Carcinosarcoma of the uteri as a third diagnosed malignancy - case report and the review of treatment modality
Journal Title: OncoReview - Year 2013, Vol 3, Issue 4
Abstract
Progress in metastatic renal cell carcinoma treatment is generally based on new registered drugs. This brings improvement of results but it also needs the choice of proper drug. The decision is especially important in initial therapy where there are few drugs with similar properties. The choice of drug in first line is based on prognostic factors and clinical profiles of drug and patient. Important are also patient’s expectations connected with treatment. COMPARZ trail shows results of comparison between sunitinib and pazopanib which both are given in first line treatment of mRCC. Based on this the decision of choosing proper drug seems to be easier.
Authors and Affiliations
Anna Walaszkowska-Czyż, Małgorzata Kuc-Rajca
Keywords
Related Articles
- EP ID EP67740
- DOI -
- Views 218
- Downloads 0
Primary cutaneous B-cell lymphoma located on the face and hard palate
[b]Introduction[/b]: Primary cutaneous B-cell lymphomas represent primary cutaneous lymphomas. The World Health Organization-European Organization for Research and Treatment of Cancer defines primary cutaneous B-cell lim...
The influence of socio-demographic factors on making a decision related to the disease and treatment in women with breast cancer
Introduction. Socio-demographic factors may affect the decision making associated with the disease and the long-term results of treatment.Objective. Exploring the relationship between socio-demographic factors of women t...
Tyrosine kinase inhibitors in hematologic malignancy: should we be concerned?
Mental disorders in cancer patients - clinical approach
Cancer patient is struggling not only with the primary disease, but also is exposed to emotional states that at unfavorable conditions and heavy burden can lead to depression, increased anxiety, and in consequence cause...
Zespół rozpadu guza
Zespół rozpadu guza jest stanem zagrożenia życia występującym u pacjentów z rozległymi nowotworami, u których pod wpływem chemioterapii bądź samoistnie dochodzi do masywnego rozpadu komórek nowotworowych z uwolnieniem ic...